- Home
- ACRS vs BFIN Comparison
ACRS vs BFIN Comparison
Compare ACRS & BFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- BFIN
- Stock Information
- Founded
- ACRS 2012
- BFIN 1924
- Country
- ACRS United States
- BFIN United States
- Employees
- ACRS N/A
- BFIN N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- BFIN Savings Institutions
- Sector
- ACRS Health Care
- BFIN Finance
- Exchange
- ACRS Nasdaq
- BFIN Nasdaq
- Market Cap
- ACRS 165.7M
- BFIN 145.5M
- IPO Year
- ACRS 2015
- BFIN N/A
- Fundamental
- Price
- ACRS $1.53
- BFIN $10.96
- Analyst Decision
- ACRS Strong Buy
- BFIN
- Analyst Count
- ACRS 9
- BFIN 0
- Target Price
- ACRS $9.25
- BFIN N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- BFIN 43.1K
- Earning Date
- ACRS 08-11-2025
- BFIN 08-12-2025
- Dividend Yield
- ACRS N/A
- BFIN 3.60%
- EPS Growth
- ACRS N/A
- BFIN N/A
- EPS
- ACRS N/A
- BFIN 0.36
- Revenue
- ACRS $17,777,000.00
- BFIN $48,547,000.00
- Revenue This Year
- ACRS N/A
- BFIN N/A
- Revenue Next Year
- ACRS $8.11
- BFIN $6.40
- P/E Ratio
- ACRS N/A
- BFIN $31.18
- Revenue Growth
- ACRS N/A
- BFIN N/A
- 52 Week Low
- ACRS $1.05
- BFIN $10.92
- 52 Week High
- ACRS $5.17
- BFIN $13.97
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- BFIN 34.91
- Support Level
- ACRS $1.46
- BFIN $11.41
- Resistance Level
- ACRS $1.86
- BFIN $11.78
- Average True Range (ATR)
- ACRS 0.12
- BFIN 0.26
- MACD
- ACRS -0.02
- BFIN -0.08
- Stochastic Oscillator
- ACRS 17.54
- BFIN 3.96
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About BFIN BankFinancial Corporation
BankFinancial Corp is a full-service, national bank providing banking, financial planning and fiduciary services to individuals, families and businesses in the Chicago metropolitan area and on a regional or national basis for commercial finance, healthcare finance, equipment finance, commercial real estate finance and treasury management business customers. The Bank offers its customers a broad range of loan, deposit, trust and other financial products and services through approximately 18 full-service banking offices located in Cook, DuPage, Lake and Will Counties, Illinois and through its Internet Branch.